UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2240-6
Program Prior Authorization/Medical Necessity
Medications Lupkynis® (voclosporin)
P&T Approval Date 6/2021, 6/2022, 9/2022, 9/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Lupkynis is a calcineurin-inhibitor immunosuppressant indicated in combination with a
background immunosuppressive therapy regimen for the treatment of adult patients with active
lupus nephritis (LN).
Limitation of use:
Safety and efficacy of Lupkynis have not been established in combination with
cyclophosphamide. Use of Lupkynis is not recommended in this situation.
2. Coverage Criteriaa:
A. Initial Authorization
1. Lupkynis will be approved based on ALL of the following criteria:
a. Diagnosis of active lupus nephritis
-AND-
b. Provider attestation to one of the following:
(1) Diagnosis is biopsy proven
-OR-
(2) Biopsy is contraindicated in the patient
-AND-
c. Prescribed in combination with a background immunosuppressive therapy regimen (e.g.,
mycophenolate mofetil and corticosteroids)
-AND-
d. Patient is not receiving Lupkynis in combination with either of the following:
(1) Cyclophosphamide
(2) Benlysta (belimumab)
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
e. Prescribed by one of the following:
(1) Nephrologist
(2) Rheumatologist
Authorization will be issued for 12 months.
B. Reauthorization
1. Lupkynis will be approved based on the following criteria:
a. Documentation of positive clinical response to Lupkynis therapy
-AND-
b. Prescribed in combination with a background immunosuppressive therapy regimen (e.g.,
mycophenolate mofetil and corticosteroids)
-AND-
c. Patient is not receiving Lupkynis in combination with either of the following:
(1) Cyclophosphamide
(2) Benlysta (belimumab)
-AND-
d. Prescribed by one of the following:
(1) Nephrologist
(2) Rheumatologist
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program.
• Supply limitations may be in place.
4. References:
1. Lupkynis [package insert]. Rockville, MD: Aurinia Pharma U.S., Inc.; April 2024.
© 2025 UnitedHealthcare Services, Inc.
2
2. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in
systemic lupus erythematosus revisited [published correction appears in Kidney Int. 2004
Mar;65(3):1132]. Kidney Int. 2004;65(2):521-530.
3. Bomback AS, Appel GB; Lupus nephritis: Diagnosis and classification. In: UpToDate, Waltham,
MA. (Accessed on March 31, 2025)
4. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for
screening, treatment, and management of lupus nephritis. Arthritis care & research.
2012;64(6):797-808.
5. Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and
Transplant Association - European Renal Association. 2016;31(6):904-913.
6. Rovin BH, Caster DJ, Cattran DC, et al. Management and treatment of glomerular diseases (part
2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies
Conference. Kidney international. 2019;95(2):281-295.
7. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the
Management of Glomerular Diseases. Kidney Int. 2021;100(4):753-779.
Program Prior Authorization/Medical Necessity - Lupkynis (voclosporin)
Change Control
6/2021 New program.
6/2022 Annual review with no change to clinical criteria. Updated reference.
Added state mandate footnote.
9/2022 Removed criteria requiring progression or response failure to
immunosuppressive induction therapy. Removed state mandate trial
footnote.
9/2023 Annual review with no change to clinical criteria.
6/2024 Annual review. Updated authorization lengths to 12 months.
6/2025 Annual review. Removed 12 month attestation from reauthorization
criteria. Updated reference.
© 2025 UnitedHealthcare Services, Inc.
3